Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | Clinical Proteomics

Figure 3

From: Proteomic analysis of ERK1/2-mediated human sickle red blood cell membrane protein phosphorylation

Figure 3

Two-dimensional (2D) agglomerative cluster analysis using Z- score transformed phosphopeptide intensities across eight unique RBC treatment groups. Person correlations were used as the measure of similarity (−1 dissimilar, +1 identical) and are shown at each branch point. (A) RBCs from healthy (AA) and sickle cell (SS) patients pre-treated with or without the MEK1/2 inhibitor, U0126, followed by preparation of membrane ghosts, and their subsequent co-incubation with or without activated recombinant ERK2. (B) Cluster analysis performed only on SS (top panel) or AA (bottom panel) RBC treatment groups.

Back to article page